Lucera, a TechBio firm, launches to enhance drug development with decision intelligence, improving predictability, evidence-based insights, and efficiency

(SeaPRwire) –   TechBio startup Lucera launches, introducing decision intelligence to drug development to enhance predictability, evidence-based grounding, and efficiency

• The established pharmaceutical technology division of Molecular Health has been acquired by a group of life science and private equity investors to establish Lucera
• Delivers a robust commercial history, having successfully delivered projects for over 20 biotech, pharma, and venture capital entities globally
• Key technology asset – Dataome^® – offers distinct biological and medical context paired with AI-driven semantic integration and analytics. It converts data from hundreds of meticulously curated private and public sources, allowing clients to make smarter decisions, accelerate patient access to products, and lower R&D expenses
• Enables an early and causal grasp of new therapy development elements, such as determining suitable clinical endpoints, optimizing and simulating clinical trials, forecasting adverse effects, and spotting potential combination treatments

Heidelberg, Germany, June 02, 2026 — – Lucera GmbH, a TechBio enterprise employing proprietary technology to revolutionize pharmaceutical R&D and boost development effectiveness and efficiency via unique decision intelligence, has officially commenced operations today. The new company is backed by a consortium of institutional and private investors who purchased the pharmaceutical technology arm of Molecular Health GmbH to create this entity. Friedrich von Bohlen, PhD, takes on the role of Chief Executive Officer (CEO), while Stephan Brock, PhD, serves as Chief Technology Officer (CTO). Both possess deep experience as life sciences executives in precision medicine and drug discovery.

Lucera was created to be the divide between the abundance of biomedical data and the quality of decisions in drug development. Although pharma R&D currently has unprecedented access to data, models, and AI tools, making critical choices still demands biological context, mechanistic reasoning, and evidence that is trackable, comprehensible, and defensible. To address this, Lucera utilizes Dataome^®, its proprietary, semantically integrated biomedical knowledge base curated for over 15 years, to turn fragmented biomedical data into mechanistic, traceable, and decision-ready insights. This is paired with a Knowledge Graph linking biomedical entities, relationships, and evidence across various sources, modalities, and biological scales. Lucera holds exclusive rights to this technology. The company operates a validated commercial model, earning revenue from clients in pharma, biotech, CROs, management consulting, and investment firms.

Friedrich von Bohlen, PhD, CEO of Lucera, remarked: “Lucera equips us with the proven technology and know-how to facilitate highly informed decision-making in biopharma R&D and life science investment. We provide clients with a comprehensive view of a new drug candidate throughout its development lifecycle—spanning from target or phenotype to clinical pathway and side effect profile. By clarifying biological rationale, patient context, evidence gaps, and development risks, Lucera aids in better assessing the probability of technical success, designing more focused cohorts, generating evidence more efficiently, and planning preclinical and clinical development more strategically. Our established track record demonstrates that this elevated standard of decision quality empowers drug developers and investors to achieve greater success in program prioritization, planning, and resource allocation.”

Lucera comprises an interdisciplinary team of 25 professionals who transitioned from Molecular Health, bringing rich expertise in biomedical knowledge engineering, AI, computational biology, translational science, real-world evidence, drug development intelligence, and consulting. Headquartered in Heidelberg, Germany, the company serves a global clientele.

About Lucera GmbH
Lucera is a technology firm headquartered in Heidelberg, Germany, dedicated to bolstering decision intelligence by leveraging advanced data integration and artificial intelligence within pharmaceutical research and development. The company is built upon a solid foundation of proprietary data, expert curation, and sophisticated analytics, featuring a semantically integrated knowledge base—Dataome^®—refined over more than 15 years.
Lucera’s platform tackles critical questions regarding target and mechanism validation, indication prioritization, biomarker and patient stratification, translational evidence strategy, clinical and real-world evidence interpretation, trial design, clinical trial simulation, and asset and portfolio due diligence. These capabilities rely on Dataome^®’s robust medical and biological context and quality.
The company assists pharmaceutical and biotechnology organizations, as well as institutional and corporate investors, in pinpointing, evaluating, and advancing high-potential programs. By blending customized AI solutions with accessible Software-as-a-Service (SaaS), Lucera drives improved decision quality, heightened efficiency, and increased asset value.

About Dataome^®
Central to Lucera’s offerings is Dataome^®, a proprietary technology that integrates and contextualizes biomedical, molecular, phenotypic, and drug data. It converts fragmented biomedical evidence into mechanistic, traceable, and decision-ready insights. Dataome^® synthesizes hundreds of public and private biomedical sources into a structured, AI-ready knowledge layer. It is pan-disease and multi-modal, covering a wide spectrum including drugs, active pharmaceutical ingredients, targets, genes, variants, pathways, molecular entities, phenotypes, clinical evidence, real-world data, and disease biology. Its semantic architecture ensures AI outputs are biologically grounded, explainable, and traceable to their supporting evidence.
The Knowledge Graph underlying Dataome^® empowers Lucera to transcend isolated data points by linking evidence into biological context. This enables the generation of insights that are predictive, interpretable, reviewable, and relevant to decision-making.
Lucera merges Dataome^® and its Knowledge Graph with digital molecular twins, mechanistic models, multi-omics interpretation, real-world evidence integration, representation learning, embeddings, and orthogonal evidence convergence. Collectively, these features enable Lucera to determine if independent evidence layers support, contradict, or refine a biological hypothesis—and to convert these evaluations into actionable decision intelligence.

Lucera GmbH 
Friedrich von Bohlen, PhD
CEO
lucera@mc-services.eu

Media Relations
Katja Arnold, Eva Bauer
Phone: +49-89-210 2280
In the U.S.: Laurie Doyle
Phone: +1 339 832 0752
lucera@mc-services.eu